Company news

Rafael Holdings, Inc. news in 2026

Rafael Holdings, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update

October 29, 2026

Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type C

October 29, 2026

Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)

September 30, 2026

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

June 11, 2026

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

June 10, 2026

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”

April 22, 2026

Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

March 16, 2026

Decks in 2026